Inactive Instrument

PALA PHAR

Equities

PAL

AU0000049462

Palla Pharma Limited Reports Earnings Results for the Half Year Ended June 30, 2020

August 30, 2020 at 06:14 pm EDT

Palla Pharma Limited announced earnings results for the half year ended June 30, 2020. For the half year, the company announced total revenue was AUD 12.328 million compared to AUD 27.357 million a year ago. Operating loss was AUD 6.660 million compared to AUD 1.382 million a year ago. Net loss was AUD 9.014 million compared to AUD 4.083 million a year ago. Basic loss per share was AUD 0.0716 compared to AUD 0.0504 a year ago.

Latest news about PALA PHAR

Palla Pharma Limited Announces Resignation of Mark Licciardo as Company Secretary	22-06-21	CI
Palla Pharma Limited Announces Resignation of Simon Moore as Non-Executive Director and Chairman	22-05-22	CI
Palla Pharma Limited Announces Iain Ross's Resignation from the Board	22-04-25	CI
Palla Pharma Limited Announces Board Resignations	22-04-21	CI
An unknown buyer acquired Palla Pharma Norway As from Palla Pharma Limited.	22-03-28	CI
A consortium of local Norwegian buyers acquired Palla Pharma (UK) Limited from Palla Pharma Limited.	22-03-28	CI
Palla Pharma Enters Voluntary Administration	21-12-17	MT
Palla Pharma Enters Sale, Leaseback Deal for Coolaroo Manufacturing Site; Shares Up Nearly 3%	21-11-25	MT
Palla Pharma : Taps Clover Exec for CFO Role; Shares Slip 3%	21-10-05	MT
Palla Pharma Limited Announces Chief Financial Officer Changes	21-10-04	CI
Transcript : Palla Pharma Limited, H1 2021 Earnings Call, Sep 30, 2021	21-09-30
Palla Pharma Limited Provides Earnings Guidance for the Second Half of 2021	21-09-30	CI
Palla Pharma Limited Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-31	CI
Palla Pharma : Completes Regulatory Submissions to Ireland, Germany for Painkiller Product	21-06-23	MT
Palla Pharma : Appoints Alloga for UK Distribution Network	21-06-21	MT
Palla Pharma Limited Appoints Alloga UK Limited Widening Uk Distribution Network	21-06-20	CI
Palla Pharma : Names New CEO; Shares Soar 18%	21-05-26	MT
Palla Pharma Limited Appoints Giles Moss as Chief Executive Officer, Effective from September 1, 2021	21-05-25	CI
Palla Pharma : Launches Pain Relief Drug in UK	21-05-04	MT
Palla Pharma Limited Announces Launch of Its Co-Codamol 30/500 Caplet in the UK Market	21-05-03	CI
Palla Pharma Limited provides Production Partnership Update with M&A Pharmachem	21-05-03	CI
Palla Pharma Limited Auditor Raises 'Going Concern' Doubt	21-03-18	CI
Transcript : Palla Pharma Limited, 2020 Earnings Call, Feb 26, 2021	21-02-25
Palla Pharma Limited Provides Revenue Guidance for the Second Half of 2021	21-02-25	CI
Palla Pharma : Secures UK Approval for Manufacturing Site Change of Co-Codamol Tablets	21-02-18	MT

Chart PALA PHAR

Duration

Period

More charts

Company Profile

Palla Pharma Limited is an Australia-based vertically integrated pharmaceutical company. The Company's primary activities include production and distribution of Narcotic Raw Material (NRM), Active Pharmaceutical Ingredients (API) and Finished Dosage Formulations (FDF) for supply to international pharmaceutical markets, and the production and distribution of poppy seed for supply to international culinary markets. The Company operates through two segments: Australia and Norway. Australia segment activities include Narcotic Raw Material and Poppy Seed production and distribution. Norway segment activities include Active Pharmaceutical Ingredient and Finished Dosage production and distribution. The Company has developed a water-based extraction technology, which is used in NRM production. It operates in Victoria and Tasmania; and northern hemisphere operations based in Norway. It sources its raw materials from Australian poppy growers in Tasmania, New South Wales, and Victoria.

Sector

More about the company